These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide. Prince HM; Schenkel B; Mileshkin L Leukemia; 2007 Apr; 21(4):818-20; author reply 821. PubMed ID: 17301817 [No Abstract] [Full Text] [Related]
28. New treatments in multiple myeloma: beyond optimal treatment. Harousseau JL Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904 [No Abstract] [Full Text] [Related]
29. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Lacy MQ; Tefferi A Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284 [TBL] [Abstract][Full Text] [Related]
30. Practical considerations for multiple myeloma: an overview of recent data and current options. Lonial S Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S144-8. PubMed ID: 18952545 [TBL] [Abstract][Full Text] [Related]
31. Treatment of multiple myeloma: an emphasis on new developments. Kyle RA; Vincent Rajkumar S Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696 [TBL] [Abstract][Full Text] [Related]
32. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related]